Forge is the latest in a string of cell, gene therapy CDMO expansions: Data Byte

With its RA Capital-led $120 million series B round, Forge marks the latest cell and gene therapy-focused CDMO to announce significant expansions to its manufacturing operations.

This year alone has already seen a handful of significant fund-raisings for and acquisitions of cell and gene therapy CDMOs as demand for manufacturing services and expertise in new modalities continues to grow. ...